Thursday, November 22, 2012

Takeda's hyperlipidemia drug Rotoriga, Novartis once daily LAMA - NVA 237 and GSK's Pazopanib among others approved for NHI listing

Chuikyo recently approved 22 drugs for NHI listing. The prominent one's among these include
1) Novartis - NVA 237 - once daily LAMA for the treatment of COPD - Price Yen 199.2
2) GSK's pazopanib (Votrient) for the treatment of Malignant soft tissue tumors - Price Yen 4027
3)  Bayer's Eylea (aflibercept injection) for wet age AMD - Price Yen 159289
4) Takeda's Rotoriga capsule (Omega 3 fatty acid) for the treatment of Hyperlipidemia - Price Yen 254


Enter your email address:


Delivered by FeedBurner